ArticleArchives of medical science : AMS2026
Tangeretin prevents cardiac failure induced by reperfusion/ischaemia by inhibiting apoptosis, endoplasmic reticulum stress, and JNK/ERK pathway.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cardiac diseases constitute the leading cause of human mortality across the globe. The study was conducted to examine the cardiac preventive effects of tangeretin on H9c2 cardiomyocytes. Material and methods: Ischaemia/reperfusion was induced in H9c2 cardiomyocytes through anoxygenic conditions. CCK8 was used for estimation of the viability of cardiomyocytes. SOD, CAT, and GSH were determined by biochemical assays. Apoptosis was assessed through DAPI, EdU, and Annexin V/PI staining assays. ROS levels were determined by flow cytometry. The mRNA expression was determined by qRT-PCR, and protein expression was determined by western blotting. Results: The results showed that tangeretin treatment enhanced the proliferation of ischaemic cardiomyocytes in a time-dependent fashion. The EDU and DAPI staining assays showed that ischaemic cardiomyocytes exhibited lower proliferation rates and higher apoptosis. However, treatment with tangeretin exerted protective effects by inhibiting apoptosis in ischaemic cardiomyocytes. Additionally, annexin V/PI assay showed that tangeretin treatment reduced the percentage of the apoptotic cells in the ischaemic cardiomyocytes. The expression of Bax and caspase-3 were decreased and that of Bcl-2 was increased in ischaemic cardiomyocytes upon tangeretin treatment. The low cytometric analysis showed that tangeretin suppressed the ROS levels in ischaemic cardiomyocytes by increasing the expression of SOD, CAT, and GSH. Finally, tangeretin blocked the JNK/ERK signalling pathway in the ischaemic H9c2 cardiomyocytes. Conclusions: This study establishes the cardio-protective role of tangeretin and may pave the way for conducting more such studies in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.